Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) are effective for reducing body weight and are approved for the treatment of obesity.
GLP-1RAs can be considered as a treatment option for patients struggling with obesity.
StrongSupportsmedium confidence
The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight.
Why this rating
The claim is based on established approvals and clinical use.
Source
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Brian Tomlinson et al. · Expert Opinion on Investigational Drugs · 2016
DOI 10.1080/13543784.2016.1221925
reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →